# Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: A 110% Upside Potential Beckons Investors

- Link: https://www.directorstalkinterviews.com/mineralys-therapeutics-inc-mlys-stock-analysis-a-110-upside-potential-beckons-investors/4121247439
- Published: 2026-03-31T10:27:41+01:00
- Author: Madison Wilson

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is catching the eye of investors with
its promising pipeline and a notable 110% potential upside. This Radnor, Pennsylvania-
based biopharmaceutical company is spearheading innovative treatments in the biotechnology
sector, specifically targeting diseases driven by dysregulated aldosterone. With
a market capitalization of $1.94 billion, Mineralys is a noteworthy player in the
healthcare landscape.

The company’s flagship product, lorundrostat, is a proprietary, orally administered,
highly selective aldosterone synthase inhibitor. It aims to address significant 
cardiorenal conditions such as hypertension, chronic kidney disease, and obstructive
sleep apnea. As these conditions affect millions worldwide, the successful development
of lorundrostat could position Mineralys as a leader in an underserved market.

Despite the current trading price of $23.51, which is down slightly by 0.01%, analysts
are bullish on Mineralys, with eight buy ratings and just one hold. The stock’s 
52-week range reflects its volatility, spanning from $11.77 to $47.33, yet the average
target price of $49.38 underscores a robust belief in its growth trajectory.

The technical indicators, however, suggest a cautious approach. With a Relative 
Strength Index (RSI) of 34.54, the stock is nearing oversold territory, potentially
indicating a buying opportunity for contrarian investors. Additionally, the Moving
Average Convergence Divergence (MACD) at -1.56 aligns closely with its signal line,
suggesting a period of consolidation.

Valuation metrics paint a complex picture. The absence of a P/E ratio and negative
forward P/E of -12.85 reflect the company’s current lack of profitability, a common
trait in the biotech sector as firms invest heavily in research and development.
The company’s Return on Equity (ROE) of -36.91% and a significant negative free 
cash flow of $84.4 million emphasize its current focus on growth over profitability.

For income-focused investors, it’s important to note that Mineralys does not offer
a dividend, with a payout ratio of 0.00%. This aligns with its strategy of reinvesting
earnings into its development pipeline, a typical approach for companies at this
stage of growth.

Looking at the broader picture, Mineralys Therapeutics offers a compelling investment
thesis for those willing to embrace the inherent risks associated with biotechnology.
The potential market impact of lorundrostat, combined with a strong analyst consensus
and significant upside potential, makes MLYS a stock to watch closely. As always,
investors should weigh these factors against their risk tolerance and investment
goals.

Share on: